Claims for Patent: 7,351,813

Summary for Patent: 7,351,813

Title:	Liver-specific gene expression cassettes, and methods of use
Abstract:	In one aspect, the present invention provides nucleic acid expression cassettes that are predominantly expressed in the mammalian liver. The present invention also provides vectors comprising a nucleic acid expression cassette that is predominantly expressed in the mammalian liver. The present invention also provides methods of ameliorating the symptoms of a disease, the methods including the steps of introducing into the liver of a mammalian subject a vector comprising a nucleic acid expression cassette that encodes a polypeptide, and expressing a therapeutic amount of the polypeptide in the liver.
Inventor(s):	Miao; Carol H. (Seattle, WA), Kay; Mark A. (Los Altos Hills, CA)
Assignee:	The Board of Trustees of the Leland Stanford Junior University (Palo Alto, CA) University of Washington (Seattle, WA)
Application Number:	09/884,901
Patent Claims:	1. A nucleic acid expression cassette capable of expressing human Factor IX, wherein the cassette is predominantly expressed in the mammalian liver, said cassette comprising: (a) a hepatic locus control element consisting of SEQ ID NO:4 or SEQ ID NO:9; (b) a heterologous hepatic promoter located 3' to the hepatic locus control element, said promoter consisting of SEQ ID NO: 5; (c) a Factor IX coding sequence located 3' to the hepatic promoter, said coding sequence comprising SEQ ID NO:2; (d) a polyadenylation signal located 3' to the intron sequence, said polyadenylation signal consisting of SEQ ID NO:6; and (e) an intron located 3' to the hepatic promoter and 5' to the polyadenylation signal, wherein said intron consists of SEQ ID NO:1, wherein elements (a), (b), (c), (d) and (e) are operably linked to express the polypeptide encoded by the coding sequence. 2. The expression cassette of claim 1, wherein said cassette directs expression of a therapeutic amount of Factor IX in liver cells for a period of at least 100 days, and further wherein said cassette is expressed in an animal or as a component of a recombinant adeno-associated virus (AAV) vector. 3. The expression cassette of claim 1, wherein said cassette directs expression of a therapeutic amount of the polypeptide in liver cells for a period of at least 300 days, and further wherein said cassette is expressed in an animal or as a component of a recombinant adeno-associated virus (AAV) vector. 4. The expression cassette of claim 1, wherein said cassette directs expression of a therapeutic amount of the polypeptide in liver cells for a period of at least 500 days, and further wherein said cassette is expressed in an animal or as a component of a recombinant adeno-associated virus (AAV) vector. 5. A nucleic acid expression cassette capable of expressing human Factor IX, wherein the cassette is predominantly expressed in the mammalian liver, said cassette comprising: (a) a hepatic locus control element consisting of SEQ ID NO:4 or SEQ ID NO:9; (b) a hepatic promoter located 3' to the hepatic locus control element, said promoter consisting of SEQ ID NO:5; (c) a Factor IX coding sequence located 3' to the hepatic promoter, said coding sequence comprising SEQ ID NO:2; (d) a polyadenylation signal located 3' to the intron sequence, said polyadenylation signal consisting of SEQ ID NO:6; and (e) an intron located 3' to the hepatic promoter and 5' to the polyadenylation signal, wherein said intron consists of SEQ ID NO:1, and (f) an untranslated region located 3' to the coding region and the intron, said untranslated region consisting of SEQ ID NO:7; wherein elements (a), (b), (c), (d) and (e) are operably linked to express the polypeptide encoded by the coding sequence. 6. The expression cassette of claim 5, wherein said cassette directs expression of a therapeutic amount of Factor IX in liver cells for a period of at least 100 days, and further wherein said cassette is expressed in an animal or as a component of a recombinant adeno-associated virus (AAV) vector. 7. The expression cassette of claim 5, wherein said cassette directs expression of a therapeutic amount of the polypeptide in liver cells for a period of at least 300 days, and further wherein said cassette is expressed in an animal or as a component of a recombinant adeno-associated virus (AAV) vector. 8. The expression cassette of claim 5, wherein said cassette directs expression of a therapeutic amount of the polypeptide in liver cells for a period of at least 500 days, and further wherein said cassette is expressed in an animal or as a component of a recombinant adeno-associated virus (AAV) vector.

Details for Patent 7,351,813

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986		2020-06-20
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132			2020-06-20
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132			2020-06-20